Faculty: Jonathan Coleman, MD, Caroline Moore, MD and Ardeshir Rastinehad, MD

Moderators: Andre Abreu, MD and Tom Polascik, MD

Jonathan Coleman, MD 

Positions and Employment 

2006 - 2013 Assistant Attending, Memorial Sloan Kettering Cancer Center, New York, NY

2016 - Present Assistant Professor, Weill Cornell Medical Center, New York, NY

2019 - Present Associate Attending Surgeon, Memorial Hospital for Cancer and Allied Diseases, New York, NY


Other Experience and Professional Memberships

1998 - Present Member, American Urological Association

1999 - Present Member, Alpha Omega Alpha Honor Society

2002 - Present Member, Society of Urologic Oncology

2002 - Present Member, American Board of Urology

2007 - Present Member, AMerican Urological Association - New York Section



1996 Charles Horn Leadership Award

2000 Alpha Omega Alpha Honor Society

2002 Gerald P. Murphy Scholar in Urologic Oncology

2002 New York Academy of Medicine - Chief Reisdents Debate Winner

2002 Outstanding Program Presentation

2002 Pfizer Scholars in Urology Award

2005 Mentor Recognition Award

2007 Outstanding Teacher Award`

2012 Outstanding Paper Award


Caroline Moore, MD

Caroline Moore is the first woman in the UK to become a Professor of Urology. She is passionate about improving the diagnostic and treatment pathway for men with prostate cancer, using the latest in imaging technology, decision support and outcomes measurement. She has a particular interest in the use of MRI in the diagnosis and active surveillance of prostate cancer, and had led international consensus and group work in this area, including the START1 consensus on reporting studies of MRI-guided biopsy, the PRECISE consensus on reporting MRI in men on active surveillance for prostate cancer and the PRECISION study demonstrating the superiority of an MRI-targeted prostate cancer diagnosis pathway. She also studies the impact of prostate cancer diagnosis and treatment on patient reported outcome measures.

She leads national and international work in this area, supported by major funders including Movember, Prostate Cancer UK, the National Institute for Health Research, the Medical Research Council and Cancer Research UK. She is a member of the International PIRADS committee on prostate MRI. She is Head of Urology, University College London, and the Integrated Academic Training lead for Urology at University College London.


Ardeshir Rastinehad, MD

Dr. Art Rastinehad, D.O. initially joined the faculty at Northwell Health in 2011. Most recently, he was named Northwell Health’s System Director for Prostate Cancer at the Cancer Institute and the Vice Chair at the Smith Institute for Urology at Lenox Hill Hospital (January 2020). He has expertise in a wide array of interventional radiological and surgical techniques, including image guided procedures, prostate artery embolization, laparoscopic and robotic surgery. These hybrid skills were developed under the patience and kindness of his mentors Gopal Badlani (uro), Peter Choyke (rad), Louis Kavoussi (uro), Marston Linehan (uro), Igor Lobko (rad), Peter Pinto (uro), David N. Siegel (rad), Arthur Smith (uro), and Bradford Wood (rad).    

Dr. Rastinehad has dedicated his career to research and education. As a medical student he was awarded a full-scholarship as a teaching fellow in anatomy for his last three years of medical school. During this time Dr. Rastinehad joined the research group at the North Shore/Long Island Jewish (NSLIJ) Department of Urology and the Division of Interventional Radiology. His early research on Selective Arterial Prostatic Embolization (SAPE) for patients with refractory hematuria secondary to radiation prostatitis laid the foundation for his multidisciplinary approach, subsequently completing a urology residency and interventional radiology fellowship at North Shore LIJ in 2009. Soon after, Dr. Rastinehad trained at the National Cancer Institute (2009-2011) as an Interventional Urologic Oncologist and is the first urologist to be dual fellowship trained in Urologic Oncology and Interventional Radiology. 

Dr. Rastinehad has also authored and implemented several clinical trials of new techniques in the diagnosis and treatment of localized prostate cancer. In 2011 at Northwell Heath, he was the principal investigator for a Phase III clinical trial using MRI/Ultrasound fusion technology to improve prostate biopsy techniques and validated the original work from the NIH’s UOB/MIP/CIO programs. This was the first trial of this technology in the United States outside the National Institutes of Health. Dr. Rastinehad is considered one of the pioneers of this field, bringing prostate MRI and MR/US fusion guided prostate biopsy from the bench to clinical practice. 

This new clinical approach is the groundwork for the evaluation of a new technique, Focal Therapy, which treats only the diseased portion of the prostate.  While at the NIH, Dr. Rastinehad designed and authored the first trial assessing the utility of MR guided focal ablation of prostate tumors using MR US fusion biopsy data with Dr. Pinto as the PI (2010). As of May 2016, Dr Rastinehad was the first in the world to perform a gold nanoparticle directed ablation using a transperineal MR/US Fusion guided focal therapy system. This was the first-time nanoparticles were utilized to focally treat any cancer and this first series was recently published in Proceedings of the National Academy of Science (PNAS).  

Dr Rastinehad is also one of the founding executive board members of the Focal Therapy Society (along with Drs. Polascik, De La Rosette, and Sanchez-Salas), which was started in October 2019 in collaboration with the Endourological Society. The society continues to grow and establish solid scientific principles to critically evaluate, disseminate, and perform focal therapy. In addition to his leadership role within the Focal Therapy Society, Dr. Rastinehad has been the course director and/or faculty for more than 30 courses nationally and internationally at the AUA, Endourological Society, Focal Therapy Society, and Société Internationale d'Urologie. Along with Dr. Pinto, he was the course director on the first use of MR/US fusion guided prostate biopsies in 2014.  Continuing his goal to help bring these new treatments and approaches to the urologic community, he is currently developing the first Interventional Urology mobile platform combining image fusion, cone-beam CT/fluoroscopy, optical/EM tracking along with ESWL, ultrasound and the newest advances in radiation safety. These efforts will provide a platform for urologists to leverage these technologies and perform interventional treatments in their own operating rooms. 

Dr. Rastinehad’s research has been published in leading national and international medical journals. 

He has published over 200 articles, videos, and multiple textbook chapters and was the senior editor of the first comprehensive textbook on the subject, ‘Interventional Urology’, in 2016. Dr. Rastinehad continues to dedicate his time to caring for patients by researching and developing new diagnostic and therapeutic interventions for urologic diseases, as well as training the next generation of urologists. He has formalized the training required for learning the skills of interventional urology (IU) with the establishment of the first and only IU program in the world. 


Andre Abreu, MD

Assistant Professor of Clinical Urology and Radiology at the University of Southern California, Los Angeles – CA, USA.

Director of Image-guided Surgery and Focal Therapy of Prostate Cancer at USC.

He has expertise in minimally invasive and image-guided urologic surgery with focus on ablation therapy and robotic surgery for prostate cancer, and image-fusion prostate biopsy. He has published many articles in reputed peer-reviewed journals. He delivered several lectures nationally and internationally and presented numerous abstracts during the major Societies meetings, being granted with several awards.


Tom Polascik, MD

Thomas J. Polascik, MD FACS is Professor of Surgery, Duke University Medical Center. He is the Director of Surgical Technology, Duke Prostate and Urological Cancer Center. He is the founder and co-director of the International Symposium on Focal Therapy and Imaging of Prostate and Kidney Cancer that began at Duke in 2008. Dr Polascik is the Editor of the text Imaging and Focal Therapy of Early Prostate Cancer. He currently is the founder and President of the Focal Therapy Society, Duke’s Director of the Society of Urologic Oncology fellowship training program and the Genitourinary Program on Focal Therapy at the Duke Cancer Institute. He is the Medical Director of Duke Men’s Health Initiative Screening event each September and is a governing member of several medical boards and societies. His clinical and research interests focus on prostate and kidney cancer. He has authored over 350 peer-reviewed manuscripts and book chapters.